))
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications. Use cases for the DrugPatentWatch platform include: - Branded pharmaceutical global business intelligence and forecasting - Generic drug and API manufacturer portfolio management - Wholesalers preventing overstock of off-patent drugs - Healthcare payer formulary management and budget management
…
continue reading
Defination Uses Various processes in Tissue - culture
…
continue reading
Welcome to the Biotech Bytes podcast, where we sit down with Biotech and Pharma IT leaders to learn what's working in our industry. Steven Swan is the CEO of The Swan Group LLC. He has 20 years of experience working with companies and individuals to make long-term matches. Focusing on Information technology within the Biotech and Pharmaceutical industries has allowed The Swan Group to become a valued partner to many companies. Staying in constant contact with the marketplace and its trends a ...
…
continue reading
Biotechnology for Tomorrow
…
continue reading
What happens when robots, AI, and big data enter the hospital? Glenn Cohen (a professor and deputy dean at Harvard Law School) is unpacking that question in this exploration of biotechnology, ethics, medical law, and health care policy. Each week, he’ll interrogate a single technology – such as digital pills, AI-powered decision support algorithms, or digital health apps – through the lens of ethical concerns like informed consent, liability, and privacy.
…
continue reading
In the high-stakes world of pharmaceuticals, patents play a pivotal role in safeguarding intellectual property and ensuring a return on investment for drug developers. The journey of a drug patent is a complex and intricate one, spanning from the initial filing to its eventual expiry. This article delves into the nuances of this process, shedding […
…
continue reading
The quality of leadership and innovation in biotechnology is experiencing a significant transformation. Joining me today is Pasqual Zottola, Vice President of Information Technology at Acorda Therapeutics, Inc. We talk about how integrating advanced technological solutions and standout leadership principles leads to sustainable success in biotech. …
…
continue reading
In the ever-evolving pharmaceutical landscape, savvy businesses are constantly on the lookout for untapped markets and lucrative opportunities. One area that has garnered significant attention is the realm of low-competition generic drugs. These are off-patent medications that, for various reasons, have yet to attract a significant number of generi…
…
continue reading
Branded generics are generic drugs that are marketed under a brand name by the manufacturer. These products contain the same active ingredients as their brand-name counterparts but are typically sold at a lower price point. Branded generics can be an attractive option for both consumers and pharmaceutical companies, offering cost savings while leve…
…
continue reading
A recent whitepaper by Hermann Mucke summarizes the steps to performing an FTO for drug repurposing: Overview An FtO analysis determines if a new product or process can proceed without infringing third-party intellectual property (IP) rights, especially patents. It is crucial for drug repurposing projects involving known compounds that may still be…
…
continue reading
The article “The devil is in the divisional: an analysis of divisional patents, deadlines, declarations and suggestions for future practice” by Mieke Filler provides a comprehensive analysis of the strategic use of divisional patents in the pharmaceutical sector to delay generic and biosimilar market entry. Key Points Citations:[1] https://academic…
…
continue reading
Pharmaceutical companies employ various strategies to extend the commercial life and patent protection of successful drugs. Here are some key approaches with examples: New Formulations One common strategy is to develop and patent new formulations of the existing drug compound to provide benefits like reduced dosing frequency, easier administration,…
…
continue reading
Sure, here’s a more detailed explanation with examples: Drug Patent Duration Drug patents are granted by the United States Patent and Trademark Office (USPTO) for a period of 20 years from the date of filing the patent application. However, the effective commercial life of a drug patent is often much shorter due to the lengthy […]Source…
…
continue reading
In the “Patent Effect” podcast, Mustafa introduces his guest, Hakan Yum, the IP Director of Exrain Pharma, based in Sweden. The focus of the discussion is on patent litigation strategies within the pharmaceutical industry, particularly concerning biosimilars versus generics and the complexities involved. Hakan begins by distinguishing between gener…
…
continue reading
In a recent study published in the Expert Review of Medical Devices, researchers investigated the utilization of patent term extensions (PTEs) to extend regulatory timeframes for medical devices in the United States. Here are the key takeaways from their findings: Key Points: Overall, the study provides valuable insights into the evolving landscape…
…
continue reading
We're seeing a revolution in how we protect our data and systems, driven by rapidly evolving threats and the need for more sophisticated defenses. Our guest, Kelly Randis, Head of Global Information Technology at Gamida Cell Ltd., brings over three decades of IT expertise, primarily in the pharmaceutical industry. We discuss how AI is reshaping sec…
…
continue reading
Science isn't just about discovery; it's about doing it right to ensure reliability and validity. Joining me is Jonathon Hill, an epitome of a scientist, educator, innovator, and the Co-founder and Vice President of Science and Technology at Wasatch Biolabs. Although trained initially as a premed, Jonathon's professional journey took a deep dive in…
…
continue reading
The intersection of data and artificial intelligence forms the cornerstone of today's healthcare innovation, transforming the way we approach medical advancements. In this week’s episode, I'm excited to welcome Keshia Maughn from STATinMED, a company carving out its space with a focus on specialized data solutions in biotech. We look at the nuances…
…
continue reading
How do today’s biotech companies cultivate innovation and harness digital tools for strategic growth? In this episode, we dissect the pivotal role that digital enterprise capabilities play in transforming a company's approach to challenges in the life sciences sector. As I chat with Matt Lasmanis, Chief Technology & Innovation Officer at Sage Thera…
…
continue reading
Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate drug development and reduce costs. This book chapter provides a comprehensive overview of the principles, strategies, and real-world examples of successful drug repurposing efforts. The chapter highlights s…
…
continue reading
The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent study published in the Future Journal of Pharmaceutical Sciences evaluates the impact of AI on drug discovery and pharmaceutical product development in China. The research highlights the benefits and…
…
continue reading
A paper presented at the 2nd International Conference on Systems Medicine, AI, and Drug Repurposing proposes a novel approach to overcoming the financial barriers associated with repurposing generic drugs through interventional pharmacoeconomics (IVPE) and outcomes-based contracts. It highlights the challenges of funding clinical trials for repurpo…
…
continue reading
The diverse applications of artificial intelligence are transforming industries at an unprecedented pace, but with great breakthroughs come complex challenges. Today I'm joined by Rajvir Madan, Chief Digital and Technology Officer at Arcutis Biotherapeutics, to break down the transformative impact AI is having in our field. Our discussion spans fro…
…
continue reading
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research, conducted by Dr. Kimberly Feng and colleagues, aimed to investigate whether the introduction of biosimilars led to lower OOP spending for patients using biologi…
…
continue reading
The intersection of healthcare and technology paves the way for revolutionary patient care, shaping the future with precision and personalization. Today, the spotlights are on how getting data ready for AI applications is changing the game in healthcare. I'm thrilled to welcome Christopher J Kouzios, the Principal Owner of Kooz Technologies, an exp…
…
continue reading
A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the freedom to explore new technologies or businesses without needing prior approval. It has fueled rapid innovation in the IT industry through open APIs, platforms, and ecosystem development…
…
continue reading
How do we navigate the complexities of workforce management in the era of artificial intelligence? Today's discussion sheds light on the intricacies of HR policies as they adapt to the technological advancements in AI. I’m joined by Bill Pierce, Chief Information Officer at BioIVT, a visionary in leveraging technology to enhance business processes.…
…
continue reading
LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This guide is designed to provide information for healthcare providers to assist patients in selecting suitable medications. Patients may ask healthcare providers to prescribe versions of…
…
continue reading
GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This guide is designed to provide information for healthcare providers to assist patients in selecting suitable medications. Patients may ask healthcare providers to prescribe versions of d…
…
continue reading
The impact of AI on data management, particularly in the realm of biotechnology, is undeniable. It has fundamentally transformed how we approach and utilize vast amounts of data in this field. Joining me is Elisabeth Schwartz, the IT Head at Phathom, to explore the crucial task of preparing data for AI applications and the hurdles we face in ensuri…
…
continue reading
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic effect of a medication, play critical roles in the drug’s delivery, stability, and patient acceptability. The deci…
…
continue reading
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable insights to drive informed decision-making. Get the Excipient Reports from Amazon Empo…
…
continue reading
The convergence of technology and business savvy is reshaping the biotech landscape. Today's leaders are adept at harnessing IT to drive profitability and impact lives, turning data and innovation into strategic gold. In this episode, I sit down with Eduard De Vries, a visionary at the intersection of IT and healthcare business strategy. Eduard sha…
…
continue reading
A revolution in biotechnology is underway, with artificial intelligence at its core, but the fervor over AI adoption brings with it pressing concerns about data protection that cannot be overlooked. In this episode, I'm joined by Bob McCowan, Chief Information Officer at Regeneron, to navigate the crossroads of AI development and data security. We …
…
continue reading
The recent paper published in PLOS ONE presents a novel approach for efficiently retrieving a substantial number of patents related to specific technologies. The authors enhance an automated patent landscaping algorithm by incorporating a manageable amount of human supervision to enhance result accuracy and consistency. The effectiveness of the app…
…
continue reading
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The Orange Book, which lists FDA-approved drugs along with associated patents, serves to notify generic drug manufacturers of existing intellect…
…
continue reading
Automation has become a pivotal force in the advancement of the biotech sector, ushering in a new era of AI-driven solutions. In this episode, I'm joined by David Williamson, the CIO at Abzena and a trailblazer in biotech innovation. We're peeling back the layers of AI integration, from commercial chatbots that defy the conventional, to AI's grip o…
…
continue reading
Professor Glenn Cohen, Faculty Director of the Petrie-Flom Center at Harvard Law School interviews Dr. Rochelle Walensky, 19th Director of the Centers for Disease Control and Prevention and Senior Academic Fellow at the Petrie-Flom Center. They discuss Dr. Walensky’s career as an infectious disease clinician focused on HIV/AIDS, her experience lead…
…
continue reading
A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures is crucial for drug production. The article emphasizes the significance of developing compounds with novel structures for ne…
…
continue reading
A recent story by NPR echoes the findings of a collaboration between DrugPatentWatch and Bloomberg, which examined increasing competition between generic drug makers. The NPR article discusses the challenges in the generic drug industry, focusing on how rock-bottom prices contribute to shortages in hospitals. It highlights the closure of the Akorn …
…
continue reading
The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the pharmaceutical industry, particularly focusing on the impact of patent characteristics on settlement outcomes. Summary…
…
continue reading
Welcome to the first episode of the Biotech Bytes podcast! Today, we have an insightful conversation with Bill Wallace from Intercept Pharmaceuticals, exploring the transformative role of AI in the pharmaceutical and biotech industries. Bill talks about how working together and keeping data safe are key in these industries. He dives into the specif…
…
continue reading
Welcome to the Biotech Bytes podcast, where we sit down with Biotech and Pharma IT leaders to learn what's working in our industry. Steven Swan is the CEO of The Swan Group LLC. He has 20 years of experience working with companies and individuals to make long-term matches. Focusing on Information technology within the Biotech and Pharmaceutical ind…
…
continue reading
In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation extends beyond the boardrooms of pharmaceutical companies to encompass venture capitalists, private equity firms, and regulator…
…
continue reading
Researchers from West Virginia University College of Law have conducted a study examining the frequency of drug patent invalidations based on inequitable conduct. The findings, published in JAMA, shed light on the impact of fraud or deceit in obtaining patents related to Food and Drug Administration (FDA)-regulated products. The study reveals a sig…
…
continue reading
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending drug patent expirations and escalating costs in the United States market. With a journalistic perspective, this report delves into the…
…
continue reading
1
Maximizing Intellectual Property Value in the Biomedical Sector: A Case Study on Rucaparib Patents
A paper titled “Analysis of Strategy for Extending Patent Protection of Rucaparib” by Zhifeng Wang. discusses the strategies employed by pharmaceutical companies to extend the patent protection period of the drug Rucaparib. Rucaparib is a medication used in the treatment of ovarian cancer and is subject to various patent strategies. The article hig…
…
continue reading
1
Advancements in In Silico ADMET Modeling: A 20-Year Journey of Machine Learning in Drug Discovery at Bayer Pharma
Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical endpoints in early drug discovery. This platform is accessible to all scientists within the company and has proven valuable in assis…
…
continue reading
DrugPatentWatch has published a list of research papers citing DrugPatentWatch at https://www.drugpatentwatch.com/citations/ DrugPatentWatch.com is your key to unlocking the world of pharmaceutical research. These primary literature citations can benefit researchers, keeping them informed and connected in the ever-evolving field of drug patents. Re…
…
continue reading
Should Social Robots be Used to Provide Emotional Support? PARO is a cuddly baby seal used as an emotional companion robot in elder care. Emotional companion robots provide some of the benefits of therapy animals, without the attendant challenges of a live animal. But while emotional companion robots can provide comfort to older adults, they might …
…
continue reading
How Should We Regulate Digital Health Technology? The current digital health marketplace has been described as a wild west. Every day, consumer products making strong claims are brought to market without sufficient evidence and often withdrawn only when enforcement actions are brought against them. There are already apps that claim to detect melano…
…
continue reading
In a systematic review titled “Influencers of Generic Drug Utilization,” researchers aimed to shed light on the key factors influencing the use of generic prescription drugs in the United States. The review, published in the journal Research in Social and Administrative Pharmacy, delves into the critical need to encourage the adoption of generic dr…
…
continue reading
How AI Bias Is Affecting Health Care—And What We Can Do About It People are biased, and people build AI, so AI are biased, too. When AI is used in hospitals to treat patients, that bias comes to health care. For example, a 2019 paper in Science found that a commercial risk-prediction tool was less likely to refer equally sick Black people than whit…
…
continue reading
The article titled “Reviving an R&D Pipeline: A Step Change in the Phase II Success Rate” discusses Pfizer’s efforts to improve its research and development (R&D) productivity. The pharmaceutical industry has faced declining R&D productivity, and Pfizer aimed to address this challenge by focusing on three key areas: biology, modalities, and decisio…
…
continue reading
How secure is data collected by digital pills? Ingestible electronic sensors (IESs or “digital pills”) can be taken with or as a part of a drug in order to collect and record patient data, such as medication adherence or physiological metrics. This information can then be shared with relevant parties, including the patient, family members, and heal…
…
continue reading
